AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
2
Is your solitaire opponent actually a bot?
3
Cloudera acquires Israeli startup Octopai to advance metadata and AI integration
4
Former Snyk founder Guy Podjarny secures $125M for AI-powered software startup Tessl
5
CyberArk and Wiz join forces to enhance cloud security in multi-cloud environments
More news

Actavis

5 stories about Actavis
חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
אינפו טבע מחירי תרופות גנריות Teva generic drug prices

The Crucial Piece of Information Teva Overlooked

24.12.17|Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
default image

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
default image

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended